Marcel Loetscher

Title: Marcel Loetscher: Innovator in Chemokine Receptor Research

Introduction

Marcel Loetscher is a notable inventor based in Koeniz, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the study of chemokine receptors. With a total of 6 patents, his work has implications for therapeutic applications in immunology.

Latest Patents

Loetscher's latest patents include a method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody. This invention relates to isolated and/or recombinant mammalian IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and their variants. These proteins are characterized by their selective binding to chemokines such as IP-10 and Mig, and their ability to induce cellular responses like chemotaxis and exocytosis. Another significant patent is the method for identifying ligands, inhibitors, or promoters of CXC chemokine receptor 3. This invention outlines methods for identifying receptor function modulators, which can be used to selectively inhibit lymphocyte function for therapeutic purposes.

Career Highlights

Throughout his career, Marcel Loetscher has worked at the Theodor Kocher Institute, where he has contributed to groundbreaking research in his field. His innovative approaches have led to advancements in understanding chemokine receptor functions and their therapeutic potential.

Collaborations

Loetscher has collaborated with notable colleagues such as Bernhard Moser and Shixin Qin. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.

Conclusion

Marcel Loetscher's contributions to the field of chemokine receptor research are significant and impactful. His patents reflect a commitment to advancing medical science and improving therapeutic strategies. His work continues to inspire future innovations in immunology.